What will top the agenda of new U.S. FDA Commissioner Dr. Stephen Hahn?
The U.S. Senate confirmed Stephen Hahn as commissioner of the U.S. Food and Drug Administration in a 72-18 vote.
Main pharmaceutical industry lobbying group PhRMA and some drugmakers met with President Donald Trump to voice opposition to a bipartisan U.S. Senate bill that aims to lower prescription drug prices.
Three U.S. senators introduced a resolution in support of a moratorium and other limits on gene editing embryos.
U.S. Senator Bernie Sanders unveiled the latest version of his ambitious “Medicare-for-All” plan, moving the healthcare debate among Democratic presidential contenders to center stage in the 2020 race.
U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines.
Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.
U.S. drugmaker Pfizer Inc. said the company’s Chief Executive Albert Bourla plans to testify during February 2018 at a Senate hearing examining rising prescription drug prices.
A powerful U.S. Senate committee invited seven pharmaceutical companies to testify at a hearing during February 2019 examining rising prescription drug prices.
Healthcare stocks rallied with U.S. health insurers reaching record highs as results of the 2018 mid-term elections were seen reducing the likelihood of action to cut medical costs and programs in the world’s biggest and most profitable market.